ROCKET PHARMACEUTICALS, INC. (RCKT): M&A transaction — Rocket Pharmaceuticals closes sale of rare pediatric disease PRV for $180M

ROCKET PHARMACEUTICALS, INC.

Closed sale of Rare Pediatric Disease PRV to large pharma for gross proceeds of $180M.
PRV was granted by FDA in March 2026 with approval of KRESLADI for severe LAD-I.
Pro forma cash, cash equivalents, and investments total ~$322.6M, extending runway into Q2 2028.
Previously reported cash of $144.4M as of March 31, 2026.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

ROCKET PHARMACEUTICALS, INC. completed a disposition involving a large pharmaceutical company for $180.0 million (closed 2026-06-10).

Action: disposition
Counterparty: a large pharmaceutical company
Consideration: $180.0 million
Closing: 2026-06-10

Exact text from the filing

Sale was completed pursuant to the terms of an asset purchase agreement, dated April 26, 2026 (the “PRV APA”). Pursuant to the PRV APA, the Company received gross proceeds of $180.0 million from the buyer upon the closing of the Asset Sale. The foregoing description of the PRV APA does not purport to be complete and is subject to, and qualified in its entirety, by

View on SEC.gov

83 m&a transactions filed in the last 30 days. Browse all m&a transactions →

ROCKET PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-26-024997

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.